| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 925,377 | 1,298,041 | ||
| General and administrative | 1,918,971 | 2,076,108 | ||
| Total expenses | 2,844,348 | 3,374,149 | ||
| Loss from operations | -2,844,348 | -3,374,149 | ||
| Foreign exchange losses | -6,246 | -21,110 | ||
| Investment income | 106,640 | 136,671 | ||
| Net (loss) income | -2,743,954 | -3,258,588 | ||
| Earnings per share, basic, total | -0.36 | -0.43 | ||
| Earnings per share, diluted, total | -0.36 | -0.43 | ||
| Weighted average number of shares outstanding, basic | 7,568,981 | 7,568,981 | ||
| Weighted average shares of common stock outstanding - diluted | 7,568,981 | 7,568,981 | ||
Minerva Neurosciences, Inc. (NERV)
Minerva Neurosciences, Inc. (NERV)